drugset / Trial / NCT02438215
Study of IRX4204 for Treatment of Early Parkinson's Disease
NaSingle-groupOpen-labelTreatment
Summary
This is a single site, open-label study designed to examine dopamine transporter density using \[123I\]β-CIT SPECT imaging before and following treatment with IRX4204 for a 30-day period in early Parkinson's disease patients. In addition, clinical evaluations will be performed to evaluate the effect of IRX4204 treatment on the motor and cognitive symptoms of PD.
Timeline
- Start
- 2014-08
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IRX4204 | Small molecule | 5 mg | Oral |
| Subject | IRX4204 | Small molecule | 10 mg | Oral |
| Subject | IRX4204 | Small molecule | 20 mg | Oral |